Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein

Next Previous
X
Search
Trial Profile

Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HIV vaccine (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms EVA TAT
  • Sponsors Biosantech

    • Most Recent Events

    • 15 Mar 2016 According to Biosantech media release, based on the results of this trial, the company will put forward request for a phase III trial (see CTP 700269274) of its anti-HIV vaccine for an extensive evaluation during 2016 and intends to request a MAA for its anti-HIV vaccine in second half of 2018.
    • 15 Mar 2016 According to Biosantech media release, the detailed results of this trial have been published in the scientific journal Retrovirology.
    • 15 Mar 2016 Results published in the Biosantech media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top